Gordon E. Crofoot, n/a

The Crofoot Research Center
Houston, Texas, United States

Disclosure(s): AbbVie: Grant/Research Support; Gilead Sciences, Inc.: Grant/Research Support; Janssen: Grant/Research Support; Merck: Grant/Research Support; ViiV: Grant/Research Support

Presentation(s):

• 577 - Week 48 Results of a Phase 2 Study Evaluating Once-weekly Oral Islatravir Plus Lenacapavir

  Saturday, October 19, 2024
  2:09 PM – 2:21 PM US PT